Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...

Recent & Breaking News (NYSEAM:LCTX)

BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017

Business Wire July 20, 2017

Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting

Business Wire July 19, 2017

BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City

Business Wire July 18, 2017

BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery

Business Wire July 13, 2017

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BioTime, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire June 26, 2017

Hadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences

PR Newswire June 19, 2017

Biotime Expands & Advances Ophthalmology Portfolio

Business Wire June 19, 2017

BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial

Business Wire June 14, 2017

BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial

Business Wire June 8, 2017

How These Biotech Stocks are Faring? -- Idera Pharma, BioTime, RXi Pharma, and Tenax Therapeutics

PR Newswire May 24, 2017

BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24

Business Wire May 23, 2017

BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)

Business Wire May 23, 2017

Regenerative Technology Innovations in the Medical Market

PR Newswire April 4, 2017

BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine

Business Wire August 15, 2016

BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments

Business Wire August 9, 2016

BioTime, Inc. to Report Second Quarter Results on August 9, 2016

Business Wire July 27, 2016

BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option

Business Wire July 5, 2016

BioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual Gathering

Business Wire June 29, 2016

BioTime, Inc. Announces Closing of Public Offering of Common Stock

Business Wire June 21, 2016

BioTime, Inc. Announces Pricing of Public Offering of Common Stock

Business Wire June 16, 2016